GlassScriptPhysician profile
Serguei Castaneda
NPI 1346509460
$1,290.53
in general payments reported to CMS, 2019-2025
12 companies · $954 in 2025
The $954 reported for 2025 was more than what 83% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $134 · 2024: $202 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $258.90 | 2023-2025 | Prolaris, Myrisk |
| Dendreon Pharmaceuticals LLC | $253.05 | 2025 | Provenge |
| Novocure INC. | $212.68 | 2024-2025 | Optune Gio, Optune Lua (Novottf-200t) |
| Novartis Pharmaceuticals Corporation | $175.26 | 2024-2025 | |
| Madrigal Pharmaceuticals | $121.33 | 2025 | Rezdiffra |
| Sumitomo Pharma America, INC. | $110.00 | 2025 | Orgovyx |
| Eli Lilly and Company | $44.96 | 2025 | Verzenio |
| Progenics Pharmaceuticals, INC. | $43.72 | 2024 | |
| Teleflex LLC | $37.86 | 2025 | Barrigel |
| Pfizer INC. | $20.00 | 2025 | |
| Lilly USA, LLC | $12.77 | 2023 | Retevmo, Jaypirca, Verzenio |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serguei Castaneda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.